iCAD, Inc. (NASDAQ:ICAD) Short Interest Update

iCAD, Inc. (NASDAQ:ICAD) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 199,500 shares, an increase of 6.2% from the June 30th total of 187,900 shares. Currently, 0.8% of the shares of the stock are short sold. Based on an average daily volume of 134,000 shares, the short-interest ratio is presently 1.5 days.

Institutional Investors Weigh In On iCAD

A number of hedge funds have recently made changes to their positions in ICAD. Virtu Financial LLC boosted its stake in shares of iCAD by 55.6% in the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after purchasing an additional 7,604 shares in the last quarter. Tritonpoint Wealth LLC bought a new position in iCAD in the 4th quarter valued at approximately $83,000. Salem Investment Counselors Inc. bought a new position in iCAD in the 1st quarter valued at approximately $119,000. AMH Equity Ltd bought a new position in iCAD in the 1st quarter valued at approximately $207,000. Finally, Perritt Capital Management Inc. raised its holdings in iCAD by 7.5% in the 1st quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock valued at $225,000 after buying an additional 9,717 shares during the last quarter. 24.61% of the stock is currently owned by institutional investors and hedge funds.

iCAD Trading Up 1.5 %

ICAD opened at $1.34 on Friday. The company’s 50 day moving average is $1.39 and its 200-day moving average is $1.51. iCAD has a 1-year low of $1.18 and a 1-year high of $2.83. The company has a market cap of $35.56 million, a P/E ratio of -11.17 and a beta of 1.50.

iCAD (NASDAQ:ICAD) last posted its quarterly earnings results on Tuesday, May 14th. The technology company reported ($0.05) earnings per share for the quarter. iCAD had a negative net margin of 15.20% and a negative return on equity of 14.00%. The company had revenue of $4.95 million during the quarter.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.